AbbVie Inc. (ABBV) vs AstraZeneca PLC (AZN)

AbbVie Inc. and AstraZeneca PLC are both Drug Manufacturers General companies. AbbVie Inc. is the larger, with a market value of $467.4B against $257.8B — 1.8× the size. AstraZeneca PLC trades at the lower P/E: 24.7× against 74.7×. AbbVie Inc. grew revenue faster over the last twelve months: 10.4% against 8.61%. AstraZeneca PLC has the higher net margin (17.0% vs 9.74%) and the lower return on invested capital (11.7% vs 18.1%). Both pay a dividend; AbbVie Inc. yields more (3.57% vs 2.49%). Across the 22 metrics below, AstraZeneca PLC leads on 14 and AbbVie Inc. on 8.

Valuation

Metric ABBV AZN Drug Manufacturers General median
P/E 74.67 24.72 24.72
P/S 7.26 4.21 3.35
P/B n/m 5.13 5.00
Price to free cash flow 25.68 41.24 17.68
EV/EBITDA 20.79 13.91 13.91
EV/Sales 8.26 4.61 3.95
Earnings yield 1.34% 4.05% 2.92%
Free cash flow yield 3.89% 2.42% 4.42%

Profitability

Metric ABBV AZN Drug Manufacturers General median
Gross margin 71.48% 81.88% 72.77%
Operating margin 26.20% 22.77% 18.90%
Net margin 9.74% 17.02% 8.27%
Free cash flow margin 28.28% 10.21% 17.25%
Return on equity (208.10%) 21.95% 6.97%
Return on assets 4.61% 9.15% 2.76%
Return on invested capital 18.07% 11.67% 6.30%

Growth

Metric ABBV AZN Drug Manufacturers General median
Revenue growth (TTM) 10.39% 8.61% 6.79%
EPS growth (last fiscal year) (1.26%) 45.43% —
Revenue growth, 5-year CAGR 5.95% 17.15% 3.98%
Net income growth, 5-year CAGR (1.94%) 26.19% 0.42%

Health

Metric ABBV AZN Drug Manufacturers General median
Debt to equity (12.03) 0.59 0.63
Current ratio 0.81 0.89 1.32
Net debt to EBITDA 2.59 1.13 1.15

Dividend

Metric ABBV AZN Drug Manufacturers General median
Dividend yield 3.57% 2.49% 3.57%
Payout ratio 1.19 0.73 0.53

Size

Metric ABBV AZN Drug Manufacturers General median
Market cap 467.37b 257.79b 125.91b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack